Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (61-70 of 157) with videos related to

Pageof 16
Sort By:
Antimicrobial Agents and Chemotherapy|April 16, 2014
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionKaren D Sims, Julie Lemm, Timothy Eley, et al.
The Lancet. Gastroenterology & Hepatology|October 13, 2024
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trialRohit Loomba, Pierre Bedossa, Katharine Grimmer, et al.
Journal of Hepatology|February 27, 2013
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1Eric Lawitz, Fred Poordad, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|February 22, 2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virusEric Lawitz, Fred Poordad, Jennifer Wells, et al.
Gastroenterology|February 15, 2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated AnalysisIra M Jacobson, Eric Lawitz, Paul Y Kwo, et al.
Journal of Clinical Pharmacology|December 31, 2013
Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairmentThomas Marbury, Eric Lawitz, Robert Stonerock, et al.
The Lancet. Gastroenterology & Hepatology|March 19, 2023
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialRohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, et al.
The New England Journal of Medicine|January 4, 2013
Exploratory study of oral combination antiviral therapy for hepatitis CFred Poordad, Eric Lawitz, Kris V Kowdley, et al.
Annals of the New York Academy of Sciences|August 4, 2015
Development of sofosbuvir for the treatment of hepatitis C virus infectionEric Lawitz, Ira M Jacobson, David R Nelson, et al.
Hepatology (Baltimore, Md.)|May 1, 2026
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trialNaga Chalasani, Raj Vuppalanchi, Mazen Noureddin, et al.
Pageof 16

Showing results (61-70 of 157) with videos related to

Sort By:
Pageof 16
Antimicrobial Agents and Chemotherapy|April 16, 2014
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionKaren D Sims, Julie Lemm, Timothy Eley, et al.
The Lancet. Gastroenterology & Hepatology|October 13, 2024
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trialRohit Loomba, Pierre Bedossa, Katharine Grimmer, et al.
Journal of Hepatology|February 27, 2013
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1Eric Lawitz, Fred Poordad, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|February 22, 2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virusEric Lawitz, Fred Poordad, Jennifer Wells, et al.
Gastroenterology|February 15, 2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated AnalysisIra M Jacobson, Eric Lawitz, Paul Y Kwo, et al.
Journal of Clinical Pharmacology|December 31, 2013
Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairmentThomas Marbury, Eric Lawitz, Robert Stonerock, et al.
The Lancet. Gastroenterology & Hepatology|March 19, 2023
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialRohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, et al.
The New England Journal of Medicine|January 4, 2013
Exploratory study of oral combination antiviral therapy for hepatitis CFred Poordad, Eric Lawitz, Kris V Kowdley, et al.
Annals of the New York Academy of Sciences|August 4, 2015
Development of sofosbuvir for the treatment of hepatitis C virus infectionEric Lawitz, Ira M Jacobson, David R Nelson, et al.
Hepatology (Baltimore, Md.)|May 1, 2026
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trialNaga Chalasani, Raj Vuppalanchi, Mazen Noureddin, et al.
Pageof 16